LYSOGENE - CORPORATE | EUR11 On the way for a positive phase III read out with LYS-SAF302? Very encouraging preliminary results of AAVance phase III with LYS-SAF302 Safety signal are reassuring Final analysis is now mandatory to start discussion with health authorities
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
LYSOGENE - CORPORATE | EUR11(+253%) Positive efficacy signal from biomarker data LYS-SAF302 seems to work in the brain Favourable comparison with Abeona Therapeutics data. Next important step is the lift of clinical hold by the FDA LYS-GM101 the other asset to not forget
LYSOGENE - CORPORATE | EUR11(+338%) LYS-SAF302 is delivering milestones well on track The good news of a Fast Track designation for LYS-SAF302 LYS-SAF302 could reach EUR300m sales at peak Lysogene is the most clinically advanced company for MPSIII An agreement with Sarepta to secure the development funding
Lysogene is a French biotech present in the gene therapy area. It is focused on rare genetic diseases affecting the CNS and more particularly lysosomal storage disorders. Gene therapy is an exciting new field as illustrated by the more than 300 drugs under development and the M&A deals that have been concluded for significant amounts (Novartis/AveXis for USD8.7bn or Roche/Spark Therapeutics for potentially USD4.8bn). Lysogene has developed significant know-how in this field and is the most clini...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.